{"entity":{"id":"nct05360277","kind":"trial","name":"Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer","aka":["CAMCO2"],"tldr":"A phase 2 trial of tislelizumab and capecitabine in colorectal cancer, run by Yanhong Deng, now recruiting.","summary":"Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer is a phase 2, randomised interventional study registered as NCT05360277 by Yanhong Deng, with a registry enrolment figure of 52 participants, started 2023-08-22 and due to reach its primary completion in 2025-02-28. Interventions recorded: Tislelizumab + Capecitabine; Best supportive care. Conditions listed: Metastatic Colorectal Cancer，NED. Primary outcome: Disease-free survival. Colorectal eligibility wording from the registry: \"Surgery with integrated treatment for metastatic colorectal cancer (mCRC) and achieved a statute of no evidence of disease (NED), as determined by a multidisciplinary tumor board\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05360277","url":"https://clinicaltrials.gov/study/NCT05360277"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy"],"targets":[],"drugs":["tislelizumab","capecitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05360277","phase":"2","setting":"Maintenance Tislelizumab Combined With Capecitabine to Treat Metastatic Colorectal Cancer With No Evidence of Disease","sponsor":"Yanhong Deng","enrolled":52,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05360277/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"tislelizumab","kind":"drug","name":"Tislelizumab","route":"/drugs/tislelizumab/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}